Sifting Through Discordant Data From ESC 2025

Following the European Society of Cardiology Congress 2025, experts sat down again with host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-cards), CACP, to discuss key findings from the meeting. Kaitlin Hile, PharmD, BCCP; Robert Page, PharmD, MSPH, BCPS (AQ-cards), BCGP, FAHA, FHFSA, FCCP, FASHP; and Robert DiDomenico, PharmD, FCCP, FHFSA, FACC, reviewed new data from the meeting and parsed through their lingering questions.

For more information:

• Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction (REBOOT; NCT03596385)
• Beta-Blockers After Myocardial Infarction in Patients Without Heart Failure (BETAMI–DANBLOCK; NCT03646357, NCT03778554)
• Digitoxin in Patients With Heart Failure and Reduced Ejection Fraction (DIGIT-HF)
• Vericiguat in Patients With Chronic Heart Failure and Reduced Ejection Fraction (VICTOR): A Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial (NCT05093933)